Apellis Pharmaceuticals Inc
(NAS:APLS)
$
27.44
-5.56 (-16.85%)
Market Cap: 3.41 Bil
Enterprise Value: 3.49 Bil
PE Ratio: 0
PB Ratio: 14.12
GF Score: 39/100 
Apellis Pharmaceuticals Inc at Bank of America Healthcare Conference Transcript
May 11, 2022 / 03:40PM GMT
Release Date Price:
$35.07
(-7.49%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
It's the second day of the Bank of America Healthcare Conference. I am Tazeen Ahmad. I'm one of the senior biotech analysts here. It is my pleasure to have sitting with me on stage couple of members from the Apellis Pharmaceuticals management team. I will let Cedric and Tim and Adam introduce themselves to you first. And then Cedric, if you don't mind, give us a quick 2-minute overview of the company. And then we can go into Q&A if that's okay.
Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director
Sure. Thank you Tazeen. Thank you for inviting us. My name is Cedric Francois, CEO.
Adam J. Townsend
Apellis Pharmaceuticals, Inc. - Chief Commercial Officer
Hi everyone. Adam Townsend, Chief Commercial officer.
Timothy E. Sullivan;
Apellis Pharmaceuticals, Inc. - CFO & Treasurer
Hi, Tim Sullivan, Chief Financial Officer.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers